Early experience of COVID‐19 vaccine‐related adverse events among adolescents and young adults with rheumatic diseases: A single‐center study
Open Access
- 3 January 2022
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 25 (3) , 353-363
Abstract
Objective: Considering the concerns regarding the coronavirus disease‐2019 (COVID‐19) vaccine safety among pediatric patients with inflammatory rheumatic diseases (IRD) due to a lack of data, an urgent need for studies evaluating safety profiles of vaccines emerged.Methods: Among participants vaccinated by CoronaVac inactive SARS‐CoV‐2 or BNT162b2 messenger RNA (mRNA) COVID‐19 (Pfizer‐BioNTech) vaccine, healthy children under 18 and patients under 21 with an at least 1‐year follow‐up period in our department for a childhood‐onset rheumatic disease were included into this cross‐sectional study.Results: Overall, 246 subjects (141 [57.3%] females) (biologic group: 43, non‐biologic group: 180, healthy control group: 23) were eligible for the study. The median age was 15.34 (12.02‐20.92) years. The most common adverse events were fatigue (n = 68, 27.6%), headache (n = 44, 17.9%), myalgia (n = 38, 15.4%), arthralgia (n = 38, 15.4%), and fever (n = 35, 14.2%). Only 3 subjects (2 patients with familial Mediterranean fever, and one healthy child) were considered to experienced serious adverse events, since they required hospitalization. Local reactions were seen in 20 (8.13%), and 27 patients (12.1%) had disease flares within 1 month after the vaccines. Although it was significantly higher in those who received the BNT162b2 mRNA vaccine (P < .001), there was no significant relationship between adverse event frequency and age, gender, the existing diseases, ongoing treatment regimens and pre‐vaccination COVID‐19 histories.Conclusion: Although immunogenicity studies for efficacy of the vaccines and long‐term follow‐up studies for adverse events monitoring are required, our study indicates an acceptable safety profile of COVID‐19 vaccines and encourages children with IRD to be vaccinated.Keywords
This publication has 30 references indexed in Scilit:
- Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals of the Rheumatic Diseases, 2021
- A recently explored aspect of the iceberg named COVID-19: multisystem inflammatory syndrome in children (MIS-C)Turkish Archives of Pediatrics, 2021
- Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from DenmarkRheumatology, 2020
- Immunological considerations for COVID-19 vaccine strategiesNature Reviews Immunology, 2020
- Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemicRheumatology International, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatmentsClinical Rheumatology, 2020
- Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapiesAnnals of the Rheumatic Diseases, 2020
- SARS-CoV-2 Infection in ChildrenNew England Journal of Medicine, 2020
- Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells.Journal of Clinical Investigation, 1987